Twist Bioscience TWST Rallies On AI Drug Discovery Push

Twist Bioscience Corporation stocks have been trading up by 10.19 percent following strong synthetic biology demand and growth optimism.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TWST

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways Traders Are Watching

Twist Bioscience signed a data and services deal with Eli Lilly’s AI/ML TuneLab platform, plugging its antibody characterization workflows directly into Lilly’s drug discovery engine.
Leerink repeatedly raised its TWST price target, first to $160 then to $190, while keeping an Outperform rating and calling revenue guidance conservative.
Guggenheim more than doubled its Twist Bioscience target to $212 and reiterated a Buy rating ahead of Q3 earnings.
UBS started TWST at Neutral with a relatively high $144 target, flagging life science tools as a long-term structural growth sector.
Twist Bioscience is leaning into a “picks-and-shovels” role for AI drug discovery and guiding toward adjusted EBITDA breakeven by Q4 FY26.

Live Update At 16:46:52 EDT: On Monday, October 05, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 10.19%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TWST has been trading like a momentum name, but the numbers show why traders keep crowding in. On 2026/10/05, Twist Bioscience closed at $205, up sharply from $126.85 on 2026/09/10. That’s a powerful multi-week trend, with higher highs and higher lows almost straight up the chart.

Intraday, TWST spent most of the latest session grinding between $200 and $208, finishing near the top of the range. That tight, upward-sloping tape tells traders big money is supporting dips rather than bailing out.

Fundamentally, Twist Bioscience is still a high-growth, loss-making story. Over the last quarter, TWST posted about $118.4M in revenue with gross margin near 52%, but operating margin is deep in the red and net income was roughly -$35.1M. Cash burn is improving though: operating cash flow flipped slightly positive at about $1.1M, and free cash flow was a manageable outflow near $8.6M.

More Breaking News

The balance sheet shows around $166.8M in cash and short-term investments, low leverage, and a solid current ratio of 2.7. Management is guiding toward adjusted EBITDA breakeven in Q4 FY26, so traders are paying up now for what they expect to be a cleaner profitability story later.

Why Traders Are Zeroed In On TWST Momentum

Twist Bioscience has become one of the cleaner pure-play ways to trade the intersection of synthetic biology and AI. The recent Eli Lilly TuneLab agreement is the pivot point. Under that deal, TWST will provide antibody characterization data and services into Lilly’s AI and machine-learning drug discovery platform. In simple terms, Lilly builds the AI models, Twist Bioscience supplies the high-quality wet-lab data that trains and validates them.

For traders, that makes TWST look less like a speculative lab bet and more like a “picks-and-shovels” data supplier to the AI drug discovery rush. The market agreed. On 2026/09/16, multiple reports highlighted that Twist Bioscience shares jumped several percent after the TuneLab news crossed, and the tape has stayed strong since.

The Street is chasing the story higher. Leerink first raised its TWST target from $120 to $160 with an Outperform rating, calling revenue targets conservative given the early-stage AI opportunity. Then, as pharma adoption visibility improved, Leerink pushed again to $190. Guggenheim went even further, more than doubling its Twist Bioscience target from $107 to $212 while reiterating a Buy ahead of Q3 earnings. Even UBS, which initiated at Neutral, slapped a $144 target on TWST and highlighted that life science tools could grow faster than global GDP over time.

There are checks on the hype. Twist Bioscience clarified that its AI-designed mini-binder protein work for Anthropic is “probably sort of” already baked into its fiscal 2027 orders outlook, so traders should not expect surprise upside from that project alone. And a small share sale by CEO Emily Leproust, while notable around a parabolic move, came with disclosure that she still holds more than 600,000 shares of TWST, signaling continued alignment.

Conclusion

For active traders, TWST is a classic high-volatility, high-conviction theme play. Twist Bioscience is not cheap on traditional metrics, with a price-to-sales ratio near 29 and negative returns on equity and assets. But that’s not why the stock is at $205 instead of where it was a month ago. TWST is running because the story has shifted from “interesting lab platform” to “critical data pipe for AI-driven drug discovery,” backed by a marquee partner in Eli Lilly.

Add in strong revenue growth, expanding margins, and a clear target for adjusted EBITDA breakeven by Q4 FY26, and you get a setup where every incremental execution win or new AI collaboration becomes a potential catalyst. The steady drumbeat of higher price targets from Leerink and Guggenheim reinforces that narrative, while UBS’s Neutral stance helps define downside scenarios for traders who demand a margin of safety.

Still, nothing moves in a straight line. Insider activity, changing institutional stakes, and any stumble on the path to breakeven can trigger sharp pullbacks. That is exactly why disciplined pattern recognition and risk management matter. As Tim Sykes likes to remind traders, “The best traders aren’t right more often, they just cut losses faster and let discipline do the heavy lifting.” As Tim Bohen, lead trainer with StocksToTrade says, “A consistent trading routine beats sporadic action every time. Show up daily, and you’ll start to see the patterns others miss.”. For anyone trading TWST, that mindset may be the most important data point of all.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!